Salarius Pharmaceuticals Relocates Offices

Ticker: DCOY · Form: 8-K · Filed: Jul 28, 2025 · CIK: 1615219

Sentiment: neutral

Topics: corporate-action, address-change

TL;DR

Salarius Pharma moved its HQ on 7/28/25. New address: 2450 Holcombe Blvd, Ste J-608, Houston, TX 77021.

AI Summary

On July 28, 2025, Salarius Pharmaceuticals, Inc. filed an 8-K report. The filing indicates a change in the company's principal executive offices to 2450 Holcombe Blvd, Suite J-608, Houston, TX 77021. This move is effective as of July 28, 2025. The company previously operated under the name Flex Pharma, Inc. before changing its name on July 30, 2014.

Why It Matters

A change in principal executive offices can signal operational shifts or growth for a company. Investors should monitor if this move impacts operational efficiency or strategic direction.

Risk Assessment

Risk Level: low — This filing solely reports a change in the company's physical address, which typically carries minimal immediate risk.

Key Players & Entities

FAQ

What is the new address for Salarius Pharmaceuticals, Inc.'s principal executive offices?

The new address for Salarius Pharmaceuticals, Inc.'s principal executive offices is 2450 Holcombe Blvd, Suite J-608, Houston, TX 77021.

When was the change of address effective?

The change of address was effective as of July 28, 2025.

What was Salarius Pharmaceuticals, Inc. formerly known as?

Salarius Pharmaceuticals, Inc. was formerly known as Flex Pharma, Inc.

When did the company change its name from Flex Pharma, Inc.?

The company changed its name from Flex Pharma, Inc. on July 30, 2014.

What is the Standard Industrial Classification (SIC) code for Salarius Pharmaceuticals, Inc.?

The Standard Industrial Classification (SIC) code for Salarius Pharmaceuticals, Inc. is 2834, which corresponds to Pharmaceutical Preparations.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on July 28, 2025 regarding Salarius Pharmaceuticals, Inc. (DCOY).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing